Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
2010-022812-37Phase 2Completed
- Sponsor
- Oxford University Hospitals
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of barasertib in diffuse large B-cell lymphoma (DLBCL), sponsored by Oxford University Hospitals. Primary endpoint: Overall response rate. Started Mar 2011; status: completed.
02
Drugs
barasertib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2010-022812-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022812-37.